drugset / Trial / NCT05818683
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
Timeline
- Start
- 2023-04-26
- Primary completion
- 2027-08-31
- Completion
- 2028-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-PSMA-617 | Other / unclassified | — | Intravenous |
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Subject | Apalutamide | Small molecule | — | Oral |
| Subject | Cabazitaxel | Other / unclassified | — | Intravenous |
| Subject | Cetrelimab | Monoclonal antibody | — | Intravenous |
| Subject | Darolutamide | Other / unclassified | — | Oral |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Enzalutamide | Other / unclassified | — | Oral |
| Subject | JNJ-101556143 | Other / unclassified | — | Oral |
| Subject | Pasritamig | Other / unclassified | — | — |
| Subject | Prednisone | Other / unclassified | — | Oral |